AnaptysBio Balance Sheet Health
Financial Health criteria checks 5/6
AnaptysBio has a total shareholder equity of $88.1M and total debt of $310.8M, which brings its debt-to-equity ratio to 352.8%. Its total assets and total liabilities are $452.4M and $364.3M respectively.
Key information
352.8%
Debt to equity ratio
US$310.81m
Debt
Interest coverage ratio | n/a |
Cash | US$390.90m |
Equity | US$88.10m |
Total liabilities | US$364.29m |
Total assets | US$452.39m |
Recent financial health updates
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16Recent updates
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest
Nov 11AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business
Jul 28Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 09AnaptysBio EPS beats by $0.03, beats on revenue
May 04Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts
Mar 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 28Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth
Feb 10Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters
Dec 19AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside
Nov 30AnaptysBio (ANAB) Investor Presentation - Slideshow
Nov 18Financial Position Analysis
Short Term Liabilities: ANAB's short term assets ($406.8M) exceed its short term liabilities ($37.4M).
Long Term Liabilities: ANAB's short term assets ($406.8M) exceed its long term liabilities ($326.8M).
Debt to Equity History and Analysis
Debt Level: ANAB has more cash than its total debt.
Reducing Debt: ANAB's debt to equity ratio has increased from 1.6% to 352.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANAB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ANAB has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 15.1% each year.